Amit Goyal, MD

DocwireNews

The ECLIPSE trial, presented at TCT 2024, investigated whether orbital atherectomy (OA) provides better outcomes than conventional balloon angioplasty in patients with severely calcified coronary lesions undergoing percutaneous coronary intervention (PCI). Despite initial expectations that atherectomy could improve lesion modification and stent expansion in calcified vessels, the trial found no significant advantage of OA over balloon angioplasty for most clinical outcomes.
ECLIPSE enrolled 2,005 patients across multiple centers, randomizing them to either OA with balloon angioplasty or balloon angioplasty alone before drug-eluting stent placement. The primary endpoint was target vessel failure (TVF), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI), and ischemia-driven target vessel revascularization (TVR) at one year. The study aimed to determine if OA, by facilitating better lesion preparation, could reduce adverse events and improve stent outcomes in this challenging patient population.
Results showed that TVF rates were nearly identical between the two groups at one year: 11.5% in the OA group compared to 10.0% in the balloon angioplasty group (p = 0.28). Subgroup analyses did not identify specific patient populations that particularly benefited from OA. Additionally, procedural complications, including perforation and device-related events, were slightly higher in the OA group, although these differences were not statistically significant. There was also no significant difference in the primary imaging outcome of mean post-PCI minimal stent area by optical coherence tomography (7.67 mm2 vs 7.42 mm2, p = 0.08).
Secondary endpoints, such as stent thrombosis and acute procedural success, were similar between groups. Notably, OA led to longer procedural times, additional costs, and the need for specialized operator skills, raising questions about its routine use in this patient population when balloon angioplasty appears comparably effective.
The ECLIPSE findings suggest that OA may not provide additional clinical benefits over balloon angioplasty in treating calcified coronary lesions, challenging assumptions about atherectomy’s role in optimizing PCI outcomes. Notably, however, randomization occurred after a coronary wire was across the lesion and surely was only considered in cases with procedural equipoise for atherectomy versus balloon angioplasty for a given coronary lesion. This may have excluded patients in whom the operator felt a priori that atherectomy may be preferred.
When deciding between different calcium modification techniques, operators should continue to use their judgment, develop comfortability with different devices, and deploy intracoronary imaging guidance whenever possible. Future research might explore whether specific subpopulations or lesion types could benefit from atherectomy or alternative lesion modification devices such as intravascular lithotripsy, high-pressure balloons, and cutting or scoring balloons.

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

ECLIPSE on Orbital Atherectomy: Balloon Angioplasty Still Shines in Calcified Lesions

TCT 2024

ECLIPSE investigated whether OA provides better outcomes than conventional balloon angioplasty in calcified coronary lesions.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe